1 The vasoconstrictor activities of endothelin-2, endothelin-3, sarafotoxin S6b, human proendothelin1.38 and mouse vasoactive intestinal contractor (VIC) were studied in the isolated Krebs-Henseleit perfused mesenteric arterial bed of the rat in the presence and absence of the endothelium. The vasoconstrictor properties of endothelin-1 were studied in control preparations and in preparations treated with methylene blue or N.-nitro-L-arginine methyl ester (NAME). Finally, the direct vasodilator properties of endothelin-2, endothelin-3 and sarafotoxin S6b were studied in preparations preconstricted with methoxamine.
Introduction from a 38 amino acid precursor, proendothelinl 38 (Itoh et al., 1988) . All the endothelins contain 21 amino acids and 4 cysSince the initial characterization of porcine endothelin teine residues which are linked by disulphide bridges between (Yanagisawa et al., 1988b) , the human genome has been found residues 1 and 15 and between residues 3 and 11. Endothelin-2 to contain coding for not only the same peptide sequence shows the greatest homology with endothelin-1 and differs (Itoh et al., 1988) , now designated endothelin-1, but also for at only two positions in the smaller intramolecular loop (that two other endogenous isopeptides (Inoue et al., 1989) , namely between positions 3 and 11), whereas endothelin-3 has 6 subendothelin-2 and endothelin-3 (the latter sequence being idenstitutions relative to endothelin-1, 4 within the smaller intratical to one originally found in the rat genome; Yanagisawa et molecular loop and 2 substitutions adjacent to bridge forming al., 1988a) . It is thought that human endothelin-1 is formed cysteinyl residues. Comparative studies on the vascular actions of endothelin-2 and endothelin-3 have shown that they 1 Author for correspondence.
are both less potent than endothelin-1 at contracting porcine IVMacmiHan Press Ltd. 1990 coronary strips denuded of endothelium (Inoue et al., 1989) . However, endothelin-2 produced maximum responses which were 50% greater than those of endothelin-1 which, in turn, gave maximum responses twice as large as those of endothelin-3 (Inoue et al., 1989) . In the rat isolated perfused mesenteric bed, endothelin-3 is a partial agonist relative to endothelin-1 but is more effective at causing endothelium-dependent relaxations (Warner et al., 1989) . All of the forms encoded in the human genome increase arterial pressure in the anaesthetized, chemically-denervated rat; endothelin-2 produced responses which are of the longest duration and endothelin-3 causes the largest initial depressor responses (Inoue et al., 1989) . A further endothelin-like peptide sequence of mammalian origin, with 3 substitutions relative to endothelin-1, was found in the mouse genome by Saida et al.
T1989) and named vasoactive intestinal contractor (VIC).
A similar structure to the endothelins is possessed by the cardiotoxin sarafotoxin S6b, a constituent of the venom of the Palestinian burrowing asp Atractaspis engaddensis (Kloog et al., 1988) . Sarafotoxin S6b, like endothelin-1, is a 21 amino acid peptide which contains a hydrophobic carboxy terminus with a terminal tryptophan residue and has 2 disulphide bridges in the same positions as those of endothelin-1; of the 7 substitutions relative to endothelin-1, 4 are contained within the smaller intramolecular loop and 2 are in the 6 C-terminal residues. Functional homology between this toxin and endothelin-1 is suggested by the ability of sarafotoxin S6b to displace [1251] -endothelin-1 from rat isolated cardiac membrane fragments (Gu et al., 1989) and by the observations that sarafotoxins and endothelins also have common mechanisms of action on rat atria and brain (Ambar et al., 1989) .
We have previously shown that some alanyl-substituted analogues of endothelin-1 are active vasoconstrictors in the superior mesenteric arterial bed of the rat, even though each of these analogues is devoid of either one or both of the disulphide bridges possessed by the parent peptides (Randall et al., 1989 ). Now we describe the role of the endothelium in controlling the constrictor effects of endothelin-1, endothelin-2, endothelin-3, sarafotoxin S6b, human proendothelinl-38 and vasoactive intestinal contractor (VIC) in the isolated, Krebs-Henseleit perfused mesenteric bed. This was assessed by using the detergent 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulphonate (CHAPS) to destroy the endothelium, or, in the case of endothelin-1, either methylene blue, to inhibit the stimulation of the soluble guanylate cyclase activated by endothelium-derived relaxing faqtor (EDRF), or N.-nitro-L-arginine methyl ester, (NAME), a putative inhibitor of EDRF synthesis (Moore et al., 1990) . Additionally, we studied the direct vasorelaxant properties of endothelin-2, endothelin-3 and sarafotoxin S6b in this preparation.
Methods
The (Forstermann & Neufang, 1984) and has been used previously in the McGregor preparation, and a variety of other vascular tissues, for the same purpose (Warner et al., 1989) .
The perfused mesentery was carefully dissected away from the gastrointestinal tract, placed on a warmed Perspex block maintained at 37 + 1°C and covered with Nescofilm (Nippon Shoji Kaishi Ltd, Osaka, Japan) to avoid the surface of the tissue being damaged by evaporation.
The perfusion pressure in the mesentery was recorded, from a T-piece inserted into the perfusion circuit close to the point at which the outflow cannula was inserted into the artery, using a Bell & Howell Type 4422-0001 pressure transducer coupled to a Grass model 7D polygraph. Zero pressure was calibrated to zero flow. Since the flow rate was kept constant, changes in perfusion pressure are directly proportional to changes in vascular resistance.
After a 30min equilibration period, peptides were administered into the perfusion circuit in volumes of 100,l or less. After the first dose, the subsequent administration of peptides took place 5 min after the tissue perfusion pressure had returned to the resting basal value following the previous dose of peptide.
When required, the endothelium was removed by perfusion of the vascular bed with a 0.3% (w/v) solution of the detergent CHAPS in distilled water for 120-150s (Hiley et al., 1987) . Following this procedure, each tissue was allowed 45 min to re-equilibrate. In all preparations, before the construction of a dose-response curve for a peptide, the presence or absence of a functional endothelium was assessed by determining whether or not acetylcholine opposed noradrenaline-induced vasoconstriction (Randall et al., 1989) .
In addition to these experiments, the role of the endothelium in modulating the pressor actions of endothelin-1 was assessed by use of the guanylate cyclase inhibitor methylene blue (1pOpM final concentration in the perfusate) and the putative inhibitor of nitric oxide synthesis N<,-nitro-L-arginine methyl ester (100pM final concentration).
The vasorelaxant properties of the endothelin/sarafotoxin peptides were assessed by recording reductions in the tone established by the infusion of 0.1 mm methoxamine. In order to avoid rapid loss of the methoxamine-induced tone it was found necessary to include bovine serum albumin in the perfusate at a concentration of 5 g -' (Byfield et al., 1986) . The flow rate had also to be increased to 4 ml min 1 in order to observe an appreciable increase in mesenteric tone in response to the infusion of methoxamine. In these experiments each peptide was administered in bolus doses of 30,1 or less. (Sigma Chemical Company, Poole, Dorset) were dissolved in 0.9% NaCl (w/v). Indomethacin (Sigma) was dissolved to give a 1 mg ml-solution in 5% (w/v) sodium bicarbonate and then diluted to the required concentration in the KrebsHenseleit solution. Fraction V bovine serum albumin and CHAPS were also obtained from Sigma and methylene blue was from Fisons, Loughborough.
Statistical and data analysis
Endothelin-1, endothelin-2, endothelin-3, sarafotoxin S6b, human proendothelinl 38 and mouse vasoactive intestinal contractor (VIC) were from the Peptide Institute, Osaka, Japan and were obtained through Scientific Marketing, London. Endothelin-1, endothelin-3 and sarafotoxin S6b were dissolved in distilled water to give 100pM solutions.
Endothelin-2, human proendothelin1-38 and VIC were dissolved in distilled water containing 0.1% (v/v) acetic acid also to give a 100pUM solution. The 100pM stock solutions were frozen in 100ll aliquots at -20'C until the day of the experiment.
Results
Effect of NAME and methylene blue on the pressor activity of endothelin-J
In control preparations endothelin-1 (1 pmol-2 nmol) produced a dose-response curve ( Figure 1 . Under similar conditions, the maximum pressor response that could be obtained to noradrenaline (30 nmol) was 42.8 + 3.8 mmHg (n = 15). However, it may be seen from Figure 1 that in preparations which had been exposed to either 10pM methylene blue or 100pM NAME the Rmax values determined for endothelin-l were significantly enhanced to 36.0 + 5.1 mmHg (P < 0.01; n = 4-17) and 42.6 + 2.4 mmHg (P < 0.001; n = 3-7), respectively. Neither treatment produced significant changes in either nH (1.63 + 0.27, methylene blue; 1.58 + 0.33, NAME) or ED5o values (81.5 + 26.1 pmol, methylene blue; 57.5 + 13.7 pmol, NAME) as compared to the control values. It is interesting to Figure 2b ; Figure 3) ; the Rgnu was determined as being 7.7 + 1.4mmHg, the ED50 as 411 + 195 pmol and nH as 1.13 + 0.24 (n = 4-5). Therefore, endothelin-3 was significantly less potent than either endothelin-1 (P < 0.01) or endothelin-2 (P < 0.05) and the maximum vasoconstriction induced by endothelin-3 was significantly smaller than that induced by either endothelin-1 or endothelin-2 (P < 0.01 and P < 0.05, respectively). A difference was also observed in the time course of the pressor responses to endothelin-3 ( Figure 3 ) as compared to the other two endothelins in that they were shorter, typically lasting for around 10-15min before they returned to the resting basal perfusion pressure (Figure 3a ). Sarofotoxin S6b (1 pmol-5 nmol) was also a pressor agent in the isolated mesentery (Figure 2c ). Again the pressor responses were dose-dependent (Figure 4 ) and the fitted log dose-response curve had an Rmax of 106 + 11 mmHg, an ED50 of 345 + 86 pmol and an nH of 0.96 ± 0.05 (n = 3-5). Thus, compared to sarafotoxin S6b, endothelin-1, endothelin-2 and endothelin-3 are all partial agonists in this preparation (the significance of differences between the Rm.x for sarafotoxin S6b and those for endothelins 1-3 were P < 0.001, P < 0.001 and P < 0.001, respectively). In addition, sarafotoxin S6b was equipotent with endothelin-3 but was significantly less potent than either endothelin-l or endothelin-2 (P < 0.01 and P < 0.01, respectively). Also, as was observed with endothelin-3, the pressor responses obtained with sarafotoxin S6b were of a much shorter duration than was observed when either endothelin-1 or endothelin-2 were administered to the perfusate, characteristically lasting for only around 10-15min (Figure 4a) . VIC, the last of the 21 amino acid peptides to be investigated, produced dose-dependent increases in perfusion pressure over the dose range 1-400pmol, as shown in Figure 2d . The dose-response curve obtained had Rmax-= 12.5 + 3.9 mmHg, ED50 = 106 + 63pmol and nH = 1.35 + 0.52 (n = 4-6). Hence VIC was equipotent with endothelin-l and endothelin-2 but significantly more potent than sarafotoxin S6b (P < 0.05). Although the ED50 determined for VIC was much lower than that obtained with endothelin-3, the difference was not found to be significant. The Rm.x determined for VIC was very similar to that obtained for endothelin-2 but significantly less than that obtained with either sarafotoxin S6b (P <0.001) or endothelin-1 (P <0.05) and not significantly different from that for endothelin-3. The duration of the pressor responses obtained with this peptide was similar to those obtained with endothelin-2. The final peptide studied, human proendothelinl 38
(1 pmol-4nmol) caused increases in mesenteric perfusion pressure in doses in excess of 400pmol (Figure 2e) Pressor activities ofendothelin/sarafotoxin peptides following endothelial destruction with 0.3% CHAPS With the exception of endothelin-1 (which has previously been investigated; Randall et al., 1989) , the peptides had their pressor activity determined in the isolated mesenteric bed fol- lowing endothelial cell destruction by 0.3% CHAPS. The maximum pressor activity of endothelin-2 was enhanced (to 37.9 + 6.9 mmHg; P < 0.01; n = 5-8), relative to that found in the presence of the endothelium, following CHAPS perfusion as shown in Figure 2a . The ED50 (118 + 53pmol) and nH (2.31 + 0.96) were not significantly different from those obtained in control preparations. Similarly, Figure 3 shows that perfusion of the mesentery with CHAPS increased the responses to any given dose of endothelin-3. The log dose-response curve in Figure 2b shows that the R.. (106 + 15 mmHg) obtained with endothelin-3 was significantly augmented (P < 0.001) but the nH value of 0.89 + 0.05 was unchanged. However, removal of the endothelium significantly (P < 0.05) reduced the potency of this peptide (ED5o = 6.3 + 2.2 nmol; n = 2-10). The maximum pressor response in the absence of endothelium was not significantly different from those for sarafotoxin S6b in the presence or absence of endothelium; thus, endothelin-3 appears to be a full agonist in the absence of the vascular endothelium. Figure 2c shows that, for sarafotoxin S6b, CHAPS perfusion significantly changed neither Rmax nor nH relative to control (97.8 + 3.8 mmHg and 1.50 + 0.14 respectively; n = 2-4). However, in contrast to the findings obtained with endothelin-2 and endothelin-3, endothelial cell destruction significantly (P < 0.01) enhanced the potency of this peptide (ED50 = 111 + 15 pmol). Figure 4 shows the similarity in magnitude of responses to sarafotoxin S6b in the presence and absence of the endothelium and this contrasts with the responses for endothelin-3 which are illustrated in Figure 3 . As for endothelin-2 and endothelin-3, but in contrast to sarafotoxin S6b, the maximum pressor response to VIC was significantly enhanced (53.6 + 12.7 mmHg; n = 2-6; P < 0.01) following perfusion of the mesentery with CHAPS (Figure 2d) . However, the ED50 and nH values were not altered following endothelial cell destruction (416 + 196 pmol and 1.01 + 0.10, respectively).
Even in preparations which had been perfused with CHAPS, a full dose-response curve for human proendothelin138 could not be obtained (Figure 2e ). However, Vasorelaxant properties ofendothelin-like peptides
The 3 peptides studied, endothelin-2, endothelin-3 and sarafotoxin S6b, all caused transient decreases in the tone established in the isolated mesentery following the perfusion of the tissue with 100pM methoxamine. These responses typically lasted for around 20-30s. Endothelin-2, in doses between 2.5-50pmol, caused significant reductions in the tone (which was 70.2 + 6.8 mmHg; n = 5) established in the mesentery following the infusion of methoxamine into the perfusate (Figure 5a ). In doses in excess of 50 pmol no relaxation could be observed. Doses of 10pmol endothelin-2 or greater produced pressor responses superimposed on the methoxamine-induced tone. Table 1 and Figure 4a show that the maximum relaxation observed with endothelin-2 was obtained with 10 pmol. Similarly, endothelin-3, between the doses of 100 fmollOnmol, transiently reduced the tone (54.3 + 5.2 mmHg; n = 6) established in the mesentery by methoxamine ( Figure  5b ). The maximum relaxation observed occurred with 1 pmol endothelin-3 (Table 1 ). In doses in excess of lOpmol, no relaxation occurred and only pressor responses could be obtained. Figure Sc shows that sarafotoxin S6b, in doses from 30fmol-lOpmol, also decreased transiently the tone established by methoxamine (45.4 + 3.8 mmHg; n = 5). The maximum relaxant response was obtained with 3 pmol (Table  1 ). In doses of 1 pmol or greater, any relaxant response was rapidly followed by a more sustained pressor response. Both endothelin-3 and sarafotoxin S6b caused significant reductions in the tone established by methoxamine over much wider dose ranges than that for endothelin-2.
Effect ofendothelial destruction on the vasorelaxant properties ofendothelin-2, endothelin-3 and sarafotoxin S6b Figure 5 shows that, following the perfusion of the mesentery with 0.3% CHAPS, neither endothelin-2 (n = 4), endothelin-3 (n = 4) nor sarafotoxin S6b (n = 3) were capable of opposing the increase in perfusion pressure (48.1 + 4.5; n = 11) established by methoxamine. endothelial cell destruction clearly enhanced the pressor activity of this peptide and the responses to 400pmol-4 nmol were significantly greater (P < 0.05) than those obtained with the same doses in preparations which possessed an intact endothelium.
Discussion
All the members of the endothelin/sarafotoxin family of peptides studied here in the isolated mesenteric bed of the rat have been shown to have pressor activity, including the putative precursor human proendothelin1-38. This latter peptide was at least 30 times less potent than endothelin-1 when studied in intact tissues and at least 15 times so in tissues devoid of endothelium. These minimum estimates (the result of not being able to detect the top of the log doseresponse curve for the precursor) are somewhat less than the potency ratio of approximately 100 fold found for human proendothelin1-38 as a vasoconstrictor agent relative to endothelin-1 in rat isolated aorta (Kashiwabara et al., 1989) . In comparing the maximum responses in the presence of the endothelium, it is noteworthy that the maximum response for endothelin-3 was the lowest whereas that for sarafotoxin S6b was not only the greatest but it was approximately twice that found for noradrenaline in identical conditions. As found previously for endothelin-1 (Randall et al., 1989) , removal of the endothelium with CHAPS affected the responses to all the peptides. The maximum responses were enhanced for endothelin-2, endothelin-3, proendothelin and VIC whereas that for sarafotoxin S6b was not significantly affected. It is interesting to note that, after endothelial destruction, the maximum response for endothelin-3 was not significantly different from that for sarafotoxin S6b. The ED5o values for the peptides were not affected by the CHAPS treatment, with the exceptions of sarafotoxin S6b and endothelin-3. For endothelin-3 the ED50 was significantly increased by approximately 15 fold. It is not clear what might be responsible for this change, but it might be related to the very low maximum response obtained in the presence of endothelium and the consequent difficulties in accurately defining the log doseresponse curve. However, it is clear that the pressor responses to this peptide are virtually eliminated by the presence of the endothelium.
In the case of sarafotoxin S6b, the ED5o was reduced by 3 fold which shows that the vasoconstriction it causes is also subject to endothelial modulation. Since the maximum response obtained with this peptide was unaltered, it suggests that this is the greatest degree of constriction that can be obtained with a full agonist of the endothelin/sarafotoxin family. Since endothelin-3 was the only other peptide of the ones investigated that could cause this magnitude of pressor response, it appears that it and sarafotoxin S6b are the only full agonists amongst the natural peptides so far studied in this tissue. However, in our previous study of alanylsubstituted analogues of endothelin-l (Randall et al., 1989) , we found that [Ala3' 1]endothelin-1 gave maximum responses that were not significantly different in the presence or absence of the endothelium, being 128 + 10 and 110 + 13 mmHg respectively; thus, despite its lacking one of the 2 disulphide bridges characteristic of the endothelin/sarafotoxin family, it too is a full agonist. The other alanyl-substituted derivative studied in the previous paper, [Ala'15] endothelin-1, also gave the same maximum responses as sarafotoxin S6b in the present study. Interestingly, destruction of the endothelium did not modify the pressor responses to either of these alanylsubstituted endothelins (Randall et al., 1989) . The nature of the modulation of the pressor responses for these peptides was investigated with endothelin-1. This was done by examining the actions of methylene b'ue, an inhibitor of the stimulation of soluble guanylate cycla.e by EDRF (Martin et al., 1985) , and N.-nitro-L-arginine methyl ester, an inhibitor of the biological production of nitric oxide (Collier & Vallance, 1989; Moore et al., 1990) which accounts for the vasorelaxant action of EDRF. Both of these substances caused significant increases in the maximum pressor responses observed with endothelin-1 in the presence of endothelium. Further these maximum responses were neither significantly different from each other nor from that previously found by Randall et al. (1989) for endothelin-1 after the destruction of the endothelium. Thus, in the presence of indomethacin, the modulation of the pressor responses to the endothelin/ sarafotoxin peptides by the endothelium in the rat mesenteric bed may be ascribed entirely to the actions of EDRF released either tonically or as a result of the actions of the peptides; the enhanced responses are clearly not the effect of removing a diffusional barrier. This latter possibility arose from the work of Pohl & Busse (1989) in which it was found that, in rabbit femoral artery and vein, endothelin-l gave a pressor response when administered adventitially but not when given luminally; this difference was abolished by destruction of the endothelium.
Since the modulation of the pressor responses in the mesenteric bed was found to be due to the release of EDRF, it was decided to investigate the vasorelaxation responses which they should produce. Three of the peptides, endothelin-2, endothelin-3 and sarafotoxin S6b, were studied and all produced vasodepressor responses in the mesenteric arterial bed when it had been preconstricted with methoxamine. Since it was not possible to block selectively the pressor responses to the peptides, full dose-response relationships could not be determined for the vasorelaxant actions. Nevertheless, a striking feature of the results is that the vasorelaxation to endothelin-3 occurs at a much lower dose range (10fmol-100pmol) than the constrictor responses (30pmol-lOnmol); these results therefore confirm those of Warner et al. (1989) . Table 1 compares the maximum depressor responses and the doses at which they were obtained for the 3 peptides with those previously obtained for endothelin-1. It can be seen that the order of potency at producing the peak responses is endothelin-3 > sarafotoxin S6b > endothelin-2 > endothelin-1. This is in contrast to the order of potency of these same peptides as vasoconstrictors in the absence of endothelium (when, presumably, the only action of the peptides is that of vasoconstriction) which is sarafotoxin S6b 2 endothelin-2 > endothelin-1 > endothelin-3. Coupled with the observations that neither of the dialanyl-substituted analogues previously studied showed endothelium-dependent modulation of their pressor responses, this suggests strongly that there are two different receptor types involved in activating the vascular smooth muscle to contract and the endothelium to release EDRF. Maggi et al. (1989ab) have also found evidence, from the use of agonists, that there are multiple endothelin receptors; the C-terminal hexapeptide, endothelin16 21, can contract some smooth muscles, including the guinea-pig bronchus, rat vas deferens and rabbit pulmonary artery, but not others such as rat aorta, guinea-pig ileum and the human renal artery.
Further evidence for more than one type of endothelin receptor has been obtained by Watanabe et al. (1989) who found a single band on gel electrophoresis, of apparent molecular mass 53 kD, for [1251]-endothelin-1 cross-linked with disuccidinyl tartrate to chick cardiac membranes whereas there were 3 bands for [1251]-endothelin-3; two major bands of 34 and 46 kD and a minor one of 53 kD. They also determined the potency of each of endothelin-1, endothelin-2 and endothelin-3 at displacing the radioiodinated forms of the three peptides; endothelin-1 and endothelin-2 were generally equieffective in displacing the radioligands but endothelin-3 was more potent than either at displacing [125I]-endothelin-3 and less potent than the other two at displacing [125I]_ endothelin-1 or [1251]-endothelin-2. Although this difference in relative potency of endothelin-3 is similar to the potency sequences found in the present study; with all three radioligands sarafotoxin S6b was less potent than any of the other 3 peptides. Kloog et al. (1989) , in binding experiments with ['251 ]-sarafotoxin S6b, found different orders of potency for a number of endothelin/sarafotoxin family members in displacing the radioligand in rat aorta, atria, cerebellum and caudate nucleus which suggested three receptor subtypes: one typical of the muscles and the others occurring in one or other of the two brain regions. However, in none of these tissues was endothelin-3 more potent than either sarafotoxin S6b or endothelin-1. It would therefore seem that none of the studies are in general agreement as to a possible receptor classification, though it is possible that one of the functional receptors occurring in the mesenteric vasculature might correspond with one or other of those found by Maggi et al. (1989a,b) .
One further point that can be made about the possible receptor subtypes found in the rat mesenteric arterial bed is that endothelium-dependent modulation of their pressor responses was not observed for the two dialanyl substituted analogues of endothelin-1, [Ala"'5] endothelin-1 and [Ala3.11]endothelin-1, studied previously (Randall et al., 1989) . Thus, whilst both the disulphide bridges are not necessary for contractile action it might be concluded that the extra structural rigidity that the presence of both bonds confers is necessary for the activation of EDRF production.
The principal conclusions of the present investigation, taken with our previous study of alanyl-substituted analogues of endothelin-1, are therefore three fold. Firstly, that there are possibly two distinct receptor subtypes for the endothelin/ sarafotoxin family in the mesenteric arterial bed of the rat, one occurring on the endothelium (apparently with a structural requirement for both disulphide bridges) and the other on the vascular smooth muscle. Secondly, that vasoconstriction to all the putative native peptides with 2 disulphide bridges is modulated by the endothelium and, finally, that the modulation by the endothelium of the responses to endothelin-1, at least, is the result of the production of nitric oxide. 
